Results 111 to 120 of about 8,219 (198)

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3513-3526, October 2026.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

The Role of Upadacitinib in Refractory Dermatomyositis: A Systematic Review

Recent reports highlight upadacitinib, a JAK inhibitor that is highly selective for JAK1, as a promising treatment when used off-label for dermatomyositis.
Srivatsa, Anagha
core   +1 more source

Tripartite Interplay of Epithelial, Immune, and Microbiota Dysregulation in Crohn's Disease: Mechanisms and Translational Strategies

Immunity, Inflammation and Disease, Volume 14, Issue 10, October 2026.
ABSTRACT Background Crohn's disease (CD) is a multifactorial inflammatory bowel disease (IBD) characterized by impaired epithelial barrier integrity, excessive immune hyperactivation, and gut microbiota perturbations. Cumulative evidence supports the role of the intestinal epithelial barrier, immune system and gut microbiota in the progression of CD ...
Qing Lai, Qing‐Yun Zhang, Wei‐Peng Yang, Chun‐Ying Luo   +3 more
wiley   +1 more source

IFN‐γ‐Associated Signaling Networks in Interstitial Lung Disease Associated With Sjögren's Disease

Immunity, Inflammation and Disease, Volume 14, Issue 10, October 2026.
ABSTRACT Background Sjögren's disease (SD) is a chronic systemic autoimmune disorder that can affect multiple organ systems. Interstitial lung disease (ILD) is a clinically significant pulmonary manifestation of SD and is associated with impaired quality of life and increased mortality.
Qianqian Chen, Yuhan Li, Yiming Chen, Yuhua Su, Xiaodong Wang, Chunxiao Guan   +5 more
wiley   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

MedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis

Patient Preference and Adherence
Yan Teng, Yi Tang, Yibin Fan, Xiaohua Tao,* Yang Ding* Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou, People’s ...
Teng Y, Tang Y, Fan Y, Tao X, Ding Y
doaj  

Off-label use of upadacitinib in dermatology: a review

Objectives Upadacitinib, a selective JAK1 inhibitor, is approved for the treatment of atopic dermatitis but is increasingly used off-label in dermatology.
Xiaoli Ni, Hongtao Yu, Zhen Mu, Junkai Zhu, Kaiyu Yu   +4 more
core   +1 more source

2‐Chloro‐5‐(trifluoromethyl)aniline‐Derived Schiff Base Palladium(II) Complexes: From Molecular Design to Acute Toxicity Assessment

ChemistryOpen, Volume 15, Issue 10, October 2026.
Four new Schiff bases derived from 2‐chloro‐5‐(trifluoromethyl)aniline and their corresponding palladium(II) complexes were obtained and analyzed by multiple spectroscopic techniques. Single‐crystal X‐ray diffraction elucidated the structures of all the ligands and complexes 2 and 4. Their toxicity was assessed on Triticum aestivum L.
Andreea Elena Ştefan, Cristina Elena Dinu‐Pîrvu, Sergiu Shova, Ştefania Felicia Bărbuceanu, Teodora Venera Apostol, Diana Carolina Ilieş, Mihaela Badea, Mihaela Dinu, Robert Viorel Ancuceanu, Doina Drăgănescu, Elena Pahonţu   +10 more
wiley   +1 more source

Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis

Allergy, Volume 81, Issue 10, Page 3599-3607, October 2026.
Atopic dermatitis (AD) is characterized by microbial dysbiosis. This study aimed to evaluate the effects of abrocitinib, a JAK1‐selective inhibitor, on the skin microbiome and its potential associations with clinical outcomes in patients with AD. Abrocitinib treatment was associated with increased skin microbial diversity and decreased Staphylococcus ...
Madeline Kim, Ester Del Duca, Joel Correa Da Rosa, Juliana Pulsinelli, Yeriel Estrada, Dan Xu, Gary Chan, Allshine Chen, Erman Güler, Karen Page, Emma Guttman‐Yassky   +10 more
wiley   +1 more source

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study

Journal of Dermatological Treatment
Purpose: Atopic dermatitis (AD) adversely impacts quality of life (QoL). We evaluated the effect of upadacitinib, an oral selective Janus kinase inhibitor approved for moderate-to-severe AD, plus topical corticosteroids (+TCS) on patient-reported ...
Nina Magnolo, Michael C. Cameron, Mona Shahriari, Bob Geng, Brian M. Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G. Langley   +12 more
doaj   +1 more source